A 53 year old male with leukemia presented with optic disc pallor, attenuated retinal vessels and peripheral visual field loss confirmed on formal testing. Anti-retinal antibodies were detected by immunohistochemistry confirming the diagnosis of cancer-associated retinopathy (CAR). Hematology continued systemic chemotherapy but did not recommend systemic immune suppression as a safe treatment for the paraneoplastic eye disease. The patient received a single injection in the more severely affected eye of intravitreal triamcinolone and had initial improvement then ultimately stabilization of the visual field loss and optic nerve pallor without any side effects from the intraocular steroid injection. This case demonstrates that intraocular corticosteroid can be a safe, efficacious, local treatment option for cancer associated retinopathy.
Introduction
Cancer-associated retinopathy (CAR) is a challenging clinical entity with often delayed diagnosis and difficult 
Materials & Methods
This report details a de-identified retrospective single patient case review of an individual with known systemic leukemia, positive anti-retinal antibody testing, and clinical picture consistent with cancer associated retinopathy.
Case History
A 53 year old male with leukemia presented with small intra-retinal hemorrhages and mild optic disc pallor. Visual acuity was 20/25 in the right eye and 20/50 in the left eye. Blood pressure was well controlled and work up for diabetes mellitus was negative. Systemic chemotherapy was being administered and blood counts were responding appropriately. After a few months, the hemorrhages resolved but the patient described loss of peripheral vision.
Examination at that time revealed stable visual acuity, but more pronounced optic disc pallor, attenuated retinal vessels without hemorrhages ( Figure 1 ) and peripheral visual field loss confirmed on formal testing ( Figure 2 ).
Retinal nerve fiber layer OCT (RNFL-OCT) showed thinning of both optic nerves ( experienced fluctuations in visual acuity without CME. These changes did respond to repeated intravitreal triamcinolone injections, although the number of injections and treatment interval was not disclosed [1] . It is unclear if the same result would have been repeated if the patient's fellow eye would have received the same therapy. It is interesting that as the patient's systemic health improved over the months after the initial intravitreal steroid treatment, that the visual field and retinal nerve fiber layer studies showed stabilization in both the treated and untreated eye. As the patient was receiving intravenous immunoglobulins (IVIg) as a primary immune boosting therapy rather than a treatment specifically for cancer associated retinopathy, it is also notable that he received these treatments less frequently as the study period progressed. IV Ig is regarded as one of the systemic treatments for cancer associated retinopathy, but perhaps receiving the infusions less often allowed for intrinsic development of antibodies against the anti-retinal antibodies, allowing stabilization of the cancer associated retinopathy. As the assay for anti-retinal antibodies is qualitative rather than quantitative, it is unlikely that repeating the serum immunohistochemistry would yield additional information which would affect the course. The patient will continue to be followed and his course monitored.
